Resistance of Cancer Cells to CTL-Mediated Immunotherapy (Resistance to Targeted Anti-Cancer Therapeutics)
[amazon template=image&asin=3319178067]
This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined, and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy.
About the Author
Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes.
Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.